Lawyers Kemal Altuğ Özgün

Kemal Altuğ Özgün

Kemal Altuğ Özgün

CBC Law Firm

Altug is a legal and compliance professional with more than 19 years of experience. He started his career as a practicing lawyer at Ozgun Law Firm and then continues as an in-house counsel in multinational organizations. He served as Legal Counsel and a Board Member in Eastpharma (Deva Holding) then switched from pharma to medical devices in Beckman Coulter (a Danaher company) where he worked as Legal & Compliance Manager.

Altug continued his career as Head of Legal & Compliance at Sandoz (a Novartis division), where he focused primarily on legal department management, building and fostering the ethical culture and compliance program. Later, he decided to concentrate more on compliance and worked as an Ethics & Compliance Director at Astellas Pharma.

His practice focuses on third-party risk management, company law, labor law, healthcare regulations, anti-corruption law, employment law, white-collar crime, litigation, data privacy law, compliance, and competition law matters.


Practice Areas & Work Department

Compliance

Employment

Healthcare & Life Sciences

International Desk

 

Languages

English

Turkish

 

Memberships

Istanbul Bar Association

Ethics and Reputation Society (TEİD)

Artificial Intelligence and Technology Association (YZTD)

Regulation on Cannabis Cultivation for Active Pharmaceutical Ingredients Published

The Regulation governing the procedures for the cultivation of cannabis for the production of flowers and leaves to obtain active pharmaceutical ingredients has entered into force.

23.10.2024

İlaç Etkin Maddesi için Kenevir Yetiştiriciliği Konusunda Yönetmelik Yayımlandı

İlaç etkin maddesi elde etmek amacıyla çiçek ve yaprak üretimi için kenevir yetiştiriciliğine yönelik işlemlerin ve bu süreçteki görev ile sorumlulukların düzenlendiği Yönetmelik yürürlüğe girdi.

12.10.2024

Understanding the FCPA and FEPA: Objectives, Challenges and Impact on Global Business and Employment

Our article explores the FCPA and FEPA, detailing their objectives, challenges, and impact on global business and employment.

10.10.2024

Türkiye İlaç ve Tıbbi Cihaz Kurumu Tanıtım Yönetmeliği Taslağı İkinci Kez Görüşe Açıldı

Türkiye Tıbbi İlaç ve Tıbbi Cihaz Kurumu’nun resmi internet sitesinde, 23.09.2024 tarihinde yayımlanan duyuruya göre, daha önce dış görüşe sunulan “Beşerî Tıbbi Ürünlerin ve Özel Tıbbi Amaçlı Gıdaların Tanıtım Faaliyetleri Hakkında Yönetmelik” taslağı için alınan görüşler doğrultusunda yeni taslak yayımlanarak ikinci kez dış görüşe açılmıştır.

26.09.2024

Access to Orphan Drugs in Türkiye: A Guide for Foreign Pharmaceutical Companies

This article provides a comprehensive guide on accessing orphan drugs in Türkiye, covering the Named Patient Program (NPP) and the Compassionate Use Program (CUP). It offers critical insights for foreign pharmaceutical companies on navigating these pathways to enter the Turkish market.

02.09.2024

TİTCK Tıbbi Cihaz Yönetmelikleri Avrupa Birliği Mevzuatı ile Uyumlu Hale Getirildi

Yönetmeliklerin tıbbi cihazlar ve in vitro tanı cihazlarına ilişkin mevcut AB standartlarıyla uyumlu hale getirilmesi ve bu standartların Türkiye'de uygulanabilirliğinin sağlanmasına yönelik değişiklikler, 17 Ağustos 2024 tarihinde yayımlanmıştır.

28.08.2024

Don’t Let the Cure Be Worse Than the Ailment: Ensuring Safe Harbor in Internal Investigations - Türkiye Perspective

Our new article provides a thorough examination of internal investigations in Türkiye. It covers key topics such as whistleblowing mechanisms, labor law issues, data protection, and data transfers, offering a detailed and comprehensive overview.

27.08.2024

TİTCK Medical Device Regulations Harmonised with the European Union Legislation

Amendments to align the regulations with existing EU standards on medical devices and in vitro diagnostic devices, ensuring their applicability in Türkiye, were published on August 17, 2024.

26.08.2024
Load More
Ready to stay ahead of the curve?
Share your interest anonymously and let us guide you through the informative articles on the hottest legal topics.
|
Successful Your message has been sent